Development and validation of a novel reporter gene assay for determination of recombinant human thrombopoietin.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.107982
Abstract: Recombinant human thrombopoietin (rhTPO) was approved by the National Medical Products Administration in 2010 for the treatment of thrombocytopenia in patients with immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia. Nevertheless, no method for determining rhTPO bioactivity… read more here.
Keywords: reporter; recombinant human; gene assay; reporter gene ... See more keywords
Recombinant human thrombopoietin promotes platelet recovery in DCAG-treated patients with intermediate-high-risk MDS/hypoproliferative AML
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000033373
Abstract: Background: This study aimed to explore the effects of recombinant human thrombopoietin (rhTPO) on platelet recovery in decitabine, cytarabine, aclarubicin, and G-CSF (DCAG)-treated patients with intermediate-high-risk myelodysplastic syndrome/hypo proliferative acute myeloid leukemia. Methods: Recruited patients… read more here.
Keywords: recombinant human; risk; platelet recovery; dcag ... See more keywords